GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving...
Diagnostics
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
Cash Receipts Q2 2022 to Year to DateMELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”...
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,...
Purple City Labs Introduces OnSight, a Molecular Assay for In-house Testing of Hop Latent Viroid
OAKLAND, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Purple City Labs, a plant molecular biology company developing germplasm and technologies...
Nautilus Biotechnology Expands to San Diego
Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential...
OpGen subsidiary Ares Genetics announces granting of key patent in China
Patent covers the identification and diagnostic use of genomic variants for the diagnosis of antibiotic resistant bacteriaThe China National Intellectual...
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney diseaseLONDON...
Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480...
Dante Genomics’ sequencing hub in Dubai receives ISO 15189 Medical Laboratory accreditation to bring clinical whole genome sequencing to the next billion patients
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, announced today...
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global...
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
Qualigen Therapeutics, Inc. Benedict M. AbuganCARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”...
Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development
Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 MinuteNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) --...
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
NEWS RELEASE –REGULATED INFORMATION20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental...
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and...
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of...
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S....
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
Successful delivery of milestones triggers milestone paymentROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or...